Currently out of the existing stock ratings of Annabel Samimy, 179 are a BUY (81%), 42 are a HOLD (19%).

Annabel Samimy

Work Performance Price Targets & Ratings Chart

Analyst Annabel Samimy, currently employed at STIFEL, carries an average stock price target met ratio of 56.85% that have a potential upside of 43.16% achieved within 302 days.

Annabel Samimy’s has documented 373 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on APLS, Apellis Pharmaceuticals at 19-Dec-2025.

Wall Street Analyst Annabel Samimy

Analyst best performing recommendations are on VKTX (VIKING THERAPEUTICS).
The best stock recommendation documented was for EOLS (EVOLUS) at 1/28/2019. The price target of $27 was fulfilled within 10 days with a profit of $12.01 (80.12%) receiving and performance score of 80.12.

Average potential price target upside

of $88.88 (76.99%) on CARA (CARA THERAPEUTIC).
of $42.95 (68.2%) on CLSD (CLEARSIDE BIOMEDICAL).
of $39.2 (34.31%) on PRGO (PERRIGO COMPANY PLC).

AERI Aerie Pharmaceuticals AGN Allergan plc ANGN Angion Biomedica Corp CALT Calliditas Therapeutics CARA Cara Therapeutic ENDP Endo International PLC EOLS Evolus EVFM Evofem Biosciences FGEN FibroGen HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC MNK Mallinckrodt plc PRGO Perrigo Company PLC RDUS Schnitzer Steel Industries RETA Reata Pharmaceuticals RVNC Revance The TXMD TherapeuticsMD APLS Apellis Pharmaceuticals BHC Bausch Health Companies CLSD Clearside Biomedical SBBP Strongbridge Biopharma plc SUPN Supernus Pharmaceuticals ISEE IVERIC bio RXDX Prometheus Biosciences ZGNX Zogenix PHAS PhaseBio Pharmaceuticals VKTX Viking Therapeutics RANI Rani Therapeutics Holdings IVA Inventiva Sa RGNX Regenxbio TRVI Trevi Therapeutics

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score